GRCL
Gracell Biotechnologies Inc.
Chinese clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases, based in Suzhou, China with operations in US and China
ADRUnderlying: GRCLCUSIP: 38406L103HealthcareCN1 holder
American Depositary Shares representing Class A ordinary shares — Acquired by AstraZeneca in February 2024, delisted from Nasdaq
Total Value
$2.97M
Total Shares
491.6K
Net Share Change
-866.2K
Activity
1 selling
Investor
Value
Shares
Weight
Change
Viking Global Investors
$2.97M491.6K shares
TRIM-866.2K(-63.8%)